Angele Maki

Angele Maki serves as the Chief Business Officer at Callio Therapeutics since February 2025, following a role as Chief Business Officer at Hummingbird Bioscience. Maki is also a Board Member at Ability Biotherapeutics and a member of the Biotech Industry Advisory Council at Pear VC. As an advisor at Paradox Immunotherapeutics, Maki contributes significant expertise to the biotechnology sector. Previous positions include Senior Vice President and Head of Business Development at ReCode Therapeutics, Vice President of Venture Science at Eli Lilly and Company, Executive Director of Business Development & Licensing at Merck, Associate Director of Business Development at Genentech, and Director of the Strategic Transactions Group at Bristol Myers Squibb. Educational credentials include a PhD in Biological Chemistry from Stanford University, a postdoctoral fellowship in Molecular Biology at Scripps Research, and a B.Sc. in Chemistry from The University of Winnipeg. Maki also completed the Women in Bio Boardroom Ready Program from 2022 to 2023.